248 related articles for article (PubMed ID: 33649314)
1. Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression.
Visram A; Dasari S; Anderson E; Kumar S; Kourelis TV
Blood Cancer J; 2021 Mar; 11(3):45. PubMed ID: 33649314
[TBL] [Abstract][Full Text] [Related]
2. Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma.
Van Oekelen O; Amatangelo M; Guo M; Upadhyaya B; Cribbs AP; Kelly G; Patel M; Kim-Schulze S; Flynt E; Lagana A; Gooding S; Merad M; Jagganath S; Pierceall WE; Oppermann U; Thakurta A; Parekh S
Cell Rep Med; 2024 Jun; 5(6):101584. PubMed ID: 38776911
[TBL] [Abstract][Full Text] [Related]
3. The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape.
de Jong MME; Kellermayer Z; Papazian N; Tahri S; Hofste Op Bruinink D; Hoogenboezem R; Sanders MA; van de Woestijne PC; Bos PK; Khandanpour C; Vermeulen J; Moreau P; van Duin M; Broijl A; Sonneveld P; Cupedo T
Nat Immunol; 2021 Jun; 22(6):769-780. PubMed ID: 34017122
[TBL] [Abstract][Full Text] [Related]
4. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
5. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
Danziger SA; McConnell M; Gockley J; Young MH; Rosenthal A; Schmitz F; Reiss DJ; Farmer P; Alapat DV; Singh A; Ashby C; Bauer M; Ren Y; Smith K; Couto SS; van Rhee F; Davies F; Zangari M; Petty N; Orlowski RZ; Dhodapkar MV; Copeland WB; Fox B; Hoering A; Fitch A; Newhall K; Barlogie B; Trotter MWB; Hershberg RM; Walker BA; Dervan AP; Ratushny AV; Morgan GJ
PLoS Med; 2020 Nov; 17(11):e1003323. PubMed ID: 33147277
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma.
Pierceall WE; Amatangelo MD; Bahlis NJ; Siegel DS; Rahman A; Van Oekelen O; Neri P; Young M; Chung W; Serbina N; Parekh S; Agarwal A; Thakurta A
Clin Cancer Res; 2020 Nov; 26(22):5895-5902. PubMed ID: 32928795
[TBL] [Abstract][Full Text] [Related]
8. Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents.
Muccio VE; Saraci E; Gilestro M; Gattei V; Zucchetto A; Astolfi M; Ruggeri M; Marzanati E; Passera R; Palumbo A; Boccadoro M; Omedè P
Cytometry B Clin Cytom; 2016 Jan; 90(1):81-90. PubMed ID: 26287276
[TBL] [Abstract][Full Text] [Related]
9. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.
Wang J; De Veirman K; De Beule N; Maes K; De Bruyne E; Van Valckenborgh E; Vanderkerken K; Menu E
Oncotarget; 2015 Dec; 6(41):43992-4004. PubMed ID: 26556857
[TBL] [Abstract][Full Text] [Related]
10. Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.
Bailur JK; McCachren SS; Doxie DB; Shrestha M; Pendleton K; Nooka AK; Neparidze N; Parker TL; Bar N; Kaufman JL; Hofmeister CC; Boise LH; Lonial S; Kemp ML; Dhodapkar KM; Dhodapkar MV
JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31013254
[TBL] [Abstract][Full Text] [Related]
11. Aging-associated immune system changes in multiple myeloma: The dark side of the moon.
Visram A; Kourelis TV
Cancer Treat Res Commun; 2021; 29():100494. PubMed ID: 34837796
[TBL] [Abstract][Full Text] [Related]
12. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
Adams HC; Stevenaert F; Krejcik J; Van der Borght K; Smets T; Bald J; Abraham Y; Ceulemans H; Chiu C; Vanhoof G; Usmani SZ; Plesner T; Lonial S; Nijhof I; Lokhorst HM; Mutis T; van de Donk NWCJ; Sasser AK; Casneuf T
Cytometry A; 2019 Mar; 95(3):279-289. PubMed ID: 30536810
[TBL] [Abstract][Full Text] [Related]
13. Multiple Myeloma and the Immune Microenvironment.
Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
[TBL] [Abstract][Full Text] [Related]
14. Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma.
Perumal D; Imai N; Laganà A; Finnigan J; Melnekoff D; Leshchenko VV; Solovyov A; Madduri D; Chari A; Cho HJ; Dudley JT; Brody JD; Jagannath S; Greenbaum B; Gnjatic S; Bhardwaj N; Parekh S
Clin Cancer Res; 2020 Jan; 26(2):450-464. PubMed ID: 31857430
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.
Nijhof IS; Groen RW; Lokhorst HM; van Kessel B; Bloem AC; van Velzen J; de Jong-Korlaar R; Yuan H; Noort WA; Klein SK; Martens AC; Doshi P; Sasser K; Mutis T; van de Donk NW
Leukemia; 2015 Oct; 29(10):2039-49. PubMed ID: 25975191
[TBL] [Abstract][Full Text] [Related]
16. Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma.
Parmar H; Gertz M; Anderson EI; Kumar S; Kourelis TV
Blood Adv; 2021 Apr; 5(7):1797-1804. PubMed ID: 33787859
[TBL] [Abstract][Full Text] [Related]
17. Advances and practical use of monoclonal antibodies in multiple myeloma therapy.
Lee HC; Weber DM
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):512-520. PubMed ID: 27913523
[TBL] [Abstract][Full Text] [Related]
18. Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies.
Kourelis TV; Villasboas JC; Jessen E; Dasari S; Dispenzieri A; Jevremovic D; Kumar S
Blood Cancer J; 2019 Aug; 9(9):72. PubMed ID: 31462637
[TBL] [Abstract][Full Text] [Related]
19. E-cadherin expression on multiple myeloma cells activates tumor-promoting properties in plasmacytoid DCs.
Bi E; Li R; Bover LC; Li H; Su P; Ma X; Huang C; Wang Q; Liu L; Yang M; Lin Z; Qian J; Fu W; Liu YJ; Yi Q
J Clin Invest; 2018 Nov; 128(11):4821-4831. PubMed ID: 30277474
[TBL] [Abstract][Full Text] [Related]
20. Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression.
Wang J; De Veirman K; Faict S; Frassanito MA; Ribatti D; Vacca A; Menu E
J Pathol; 2016 Jun; 239(2):162-73. PubMed ID: 26956697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
